Preview

Научно-практическая ревматология

Расширенный поиск

Силденафил в лечении синдрома Рейно

https://doi.org/10.14412/1995-4484-2009-1311

Полный текст:

Аннотация

Синдром Рейно (СР) является чрезмерной вазоспастической реакцией на воздействие холода или эмоциональное напряжение. Клинически синдром проявляется резко очерченными участками изменения окраски кожи (побеление/посинение) пальцев кистей и стоп. В популяции, особенно в странах с холодным климатом, отмечается значительная распространенность СР, которая достигает 3-5% [1]. Различают первичный, или идиопатический, и вторичный, ассоциированный с другими заболеваниями, СР. Первичный СР характеризуется симметричностью атак вазоспазма, отсутствием изъязвлений и некрозов тканей, отсутствием признаков других заболеваний, нормальной капилляроскопической картиной, отрицательными результатами теста на антинуклеарные антитела и нормальным уровнем СОЭ [2]. При вторичном СР атаки вазоспазма обычно бывают более интенсивными, могут сопровождаться сильной болью, часто развиваются выраженные ишемические повреждения тканей в виде рецидивирующих дигитальных и иных кожных изъязвлений, гангрены фаланг пальцев кистей и стоп [3].

Список литературы

1. <div><p>Wigley FM. Raynaud phenomenon. N. Engl. J. Med., 2002, 347, 1001-8.</p><p>LeRoy EC, Medsger TA. Raynaud’s phenomenon: a proposal for classification. Clin. Exp. Rheumatol., 1992, 10, 485-8.</p><p>Hummers LK, Wigley FM. Management of Raynaud’s. Phenomenon and digital ischemic lesions in scleroderma. Rheum. Dis. Clin. North Am., 2003, 29, 293-313.</p><p>Sunderkotter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology, 2006, 45, iii33-iii35.</p><p>Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr. Opin. Rheumatol., 2005, 17, 752-60.</p><p>Thompson AE, Shea B, Welch V. et al. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum., 2001, 44(8), 1841-7.</p><p>Smith CD, McKendry RJ. Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon. Lancet, 1982, 2, 1299–301.</p><p>Fisher M, Grotta J. New uses for calcium channel blockers: therapeutic implications. Drugs, 1993, 46, 961-75.</p><p>Wollersheim H, Thien T, van’t Laar A. Nifedipine in primary Raynaud’s phenomenon and in scleroderma: oral versus sublingual hemodinamic effects. J. Clin. Pharmacol., 1987, 27, 907-13.</p><p>Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma. Curr. Opin. Rheumatol., 2002, 14, 686-93.</p><p>Herrick AL. Pathogenesis of Raynaud’s phenomenon Rheumatology, 2005, 44, 587–96.</p><p>Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum, Dis, Clin, North Am., 2005, 31, 177-86.</p><p>Kahaleh B, Matucci-Cerinic M. Raynaud’s phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum., 1995, 38, 1–4.</p><p>Vane JR, Anggard EE, Botting RM. Regulatory function of the vascular endothelium. N. Engl. J. Med., 1990, 323(1), 27-36.</p><p>Barton M, Glodny B. Endothelin receptor blockade and nitric oxide bioactivity. Cardiovasc. Res., 2001, 52(1), 161-3.</p><p>Bassenge E, Busse R. Endothelial modulation of coronary tone. Prog. Cardiovasc. Dis., 1988, 30(5), 349- 80.</p><p>Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud’s phenomenon and scleroderma. Rheum. Dis. Clin. North Am., 2003, 29(2), 275-91.</p><p>Hartmann A, Weis M, Olbrich H-G. et al. Endothelium-dependent and endothelium-independent vasomotion in large coronary arteries and in the microcirculation after cardiac transplantation. Europ. Heart J., 1994, 15(11), 1486-93.</p><p>Miyauchi T, Tomobe Y, Shiba R. et al. Involvement of endothelin in the regulation of human vascular tonus potent vasoconstrictor effect and existence in endothe- lial cells. Circulation, 1990, 81, 1874-80.</p><p>Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud’s phenomenon and scleroderma. J. Rheumatol., 2001, 28(1), 119-21.</p><p>Goto K, Kasuya Y, Maysuki N. et al. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc. Natl. Acad. Sci. USA, 1989, 86, 3915-18.</p><p>Anderson ME, Moore TL, Lunt M, Herrick AL. Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging – a non-invasive technique by which to measure microvascular dysfunction in Raynaud’s phenomenon. Rheumatol., 2004, 43, 986–91.</p><p>Anderson ME, Moore TL, Hollis S. et al. Endothelialdependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresis. Clin. Exp. Rheumatol., 2003, 21, 403</p><p>Bedarida GV, Kim D, Blaschke TF, Hoffman BB. Venodilation in Raynaud’s disease. Lancet, 1993, 342, 1451–4.</p><p>Lekakis J, Mavrikakis M, Papamicheal C. et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am. Heart J., 1998, 136, 905–12.</p><p>Freedman RF, Girgis R, Mayes MD. Endothelial and adrenergic dysfunction in Raynaud’s phenomenon and scleroderma. J. Rheumatol., 1999, 26, 2386–8.</p><p>Khan F, Belch JJF. Skin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: effects of oral L-arginine supplementation. J. Rheumatol., 1999, 26, 2389–94.</p><p>Khan F, Litchfield SJ, McLaren M. et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud’s phenom- enon. Arthritis Rheum., 1997, 40, 352–57.</p><p>La Civita L, Rossi M, Vagheggini G. et al. Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. Ann. Rheum. Dis., 1998, 57, 52-5.</p><p>Smith PJW, Ferro CJ, McQueen DS, Webb DJ. Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud’s disease. Br. J. Clin. Pharmacol., 1999, 47, 507–13.</p><p>Schlez A, Kittel M, Braun S. et al. Endothelium-dependent regulation of cutaneous microcirculation in patients with systemic scleroderma. J. Invest. Dermatol., 2003, 120, 332–4.</p><p>Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? J. Am. Coll. Cardiol., 1999, 30, 325–33.</p><p>Anderson ME, Moore TL, Hollis S. et al. Digital vascular response to topical glyceryl trinitrate, as mea- sured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatol., 2002, 41, 324–8.</p><p>Khan F, Greig IR, Newton DJ. et al. Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet, 1997, 350, 410–11.</p><p>Teh LS, Manning J, Moore T. et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br. J. Rheumatol., 1995, 34, 636–41.</p><p>Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud’s syndrome: a randomized trial. Lancet, 1999, 354, 1670–5.</p><p>Rajagopalan S, Pfenninger D, Kehrer C. et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud’s phenomenon. Implications for vascular dysfunction and progression of disease. Arthritis Rheum., 2003, 48, 1992–2000.</p><p>Biondi R, Coaccioli S, Lattanzi S. et al. Oxidant/antioxidant status in patients with Raynaud’s disease. Clin. Ter., 2008, 159(2), 77-81.</p><p>Biondi M L, Marasini B, Bassani C, Agostoni A. Increased plasma endothelin levels in patients with Raynaud’s phenomenon. N. Engl. J. Med. 1991, 324, 1139-40.</p><p>Edwards CM, Marshall JM, Pugh M. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud’s disease: the role of endothelin. Clin. Sci., 1999, 96, 577–88.</p><p>Leppert J, Ringqvist A, Karlberb BE, Ringquist I. Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud’s phenomenon. Clin. Physiol., 1998, 18, 420–5.</p><p>Zamora MR, O’Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud’s phenomenon. Lancet, 1990, 336, 1144–7.</p><p>Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J. Rheumatol., 1994, 21, 1268–76.</p><p>Korn JH, Mayes M, Matucci-Cerinic M. et al. Digital ulcers in systemic sclerosis – prevention by treatment with bosentan, and oral endothelin receptor antagonist. Arthritis Rheum., 2004, 50, 3985–93.</p><p>Lusher T.F., Barton M. Biology of the endothelium. Clin. Cardiol., 1997, 10 (suppl 11), II-3-II-10.</p><p>Lusher TF. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. Bas. Res. Cardiol., 1993, 88(SI), 15-24</p><p>Esther CR Jr, Marino EM, Howard ТЕ. et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J. Clin. Invest., 1997, 99, 2375-85.</p><p>Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem. J., 1994, 298, 249-58.</p><p>Nathan C, Xie QW. Regulation of the biosynthesis of nitric oxide. J. Biol. Chem., 1994, 269, 13725-8.</p><p>Friebe A, Koesling D. Regulation of nitric oxidesensitive guanylyl cyclase. Circ. Res., 2003, 93, 96–105.</p><p>Archer SL, Huang JM, Hampl V. et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP- dependent protein kinase. Proc. Natl. Acad. Sci. USA, 1994, 91, 7583-7.</p><p>Robertson BE, Schubert R, Hescheler J, Nelson M. cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am. J. Physiol., 1993, 265, C299-C303.</p><p>Lincoln TM, Komalavilas P, Cornwell TL. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension, 1994, 23, 1141-7.</p><p>Deruelle P, Grover T R, Storme L, Abman S H. Effects of BAY 41–2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am. J. Physiol., 2005, 288, 727-33.</p><p>Evgenov OV, Ichinose F, Evgenov NV. et al. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation, 2004, 110, 2253–9.</p><p>Leppert J, Ringqvist A, Ahlner J. et al. Seasonal variations in cyclic GMP response on whole-body cooling in women with primary Raynaud’s phenomenon. Clin. Sci. (Lond), 1997, 93(2), 175-9.</p><p>Dooley A, Gao B, Bradley N. et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology, 2006, 45, 676–84.</p><p>Corbin JD, Blount MA, Weeks JL. et al. (3H)sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol. Pharmacol., 2003, 63, 1364-72.</p><p>Guazzi M, Tumminello G, DiMarco F. et al. Influences of Sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin. Pharmacol. Ther. 2004, 76, 371–8.</p><p>Katz SD, Balidemaj K, Homma S. et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol., 2000, 36, 845–51.</p><p>Desouza C, Parulkar A, Lumpkin D. et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabet. Care, 2002, 25, 1336–9.</p><p>Halcox JP, Nour KR, Zalos G. et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J. Am. Coll. Cardiol., 2002, 40, 1232–40.</p><p>Lewis GD, Lachmann J, Camuso J. et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients wth systolic heart failure. Circulation, 2007, 115, 59-66.</p><p>Park JW, Mrowietz C, Chung N, Jung F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric prospective, double-blind, placebo-controlled, randomized cross- over study. Clin. Hemorheol. Microcirc., 2004, 31, 173–83.</p><p>Berkels R, Klotz T, Sticht G. et al. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J. Cardiovasc. Pharmacol., 2001, 37, 413– 21.</p><p>Lichtenstein JR. Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al. Arthritis Rheum., 2003, 49(2), 282-3.</p><p>Schoeffel DA, Kiekenbeck A, Dinges H. Sildenafil in the treatment of scleroderma. Ann. Rheum. Dis., 2003, 62(Suppl 1), AB0325.</p><p>Zamir B, Koman AL, SmithBP. et al. Double-blind, placebo-controlled trial of sildenafil for the management of primary Raynaud’s phenomenon. Ann. Rheum. Dis., 2004, 63(suppl 1), 484-5.</p><p>Fries R., Shariat K., von Wilmowsky H., Bohm M. Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy. Circulation, 2005, 112, 2980-5.</p><p>Gore J, Silver R Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann. Rheum. Dis., 2005, 64(9), 1387.</p><p>Kumar N, Griffits B, Allen J. Thermographic and Symptomatic Effect of a Single Dose of Sildenafil Citrate on Raynaud’s Phenomenon in Patients with Systemic Sclerosis: A Potential Treatment. J. Rheumatol., 2006, 33(9), 1918-19.</p><p>Rosenkranz S, Diet F, Karasch T. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann. Intern. Med., 2003, 139(10), 871-3.</p><p>Kumana CR, Cheung GTY, Lau CS. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann. Rheum. Dis., 2004, 63, 1522-24.</p><p>Colglazier CL, Sutej PG, O’Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J. Rheumatol., 2005, 32(12), 2440-42.</p><p>Kamata Y, Nara H, Sato H. et al. Effect of steroid pulse therapy on mixed connective tissue disease with 45 pulmonary arterial hypertension. Ann. Rheum. Dis., 2005, 64, 1236–7</p></div><br />


Для цитирования:


Алекперов Р.Т. Силденафил в лечении синдрома Рейно. Научно-практическая ревматология. 2009;47(3):38-45. https://doi.org/10.14412/1995-4484-2009-1311

For citation:


Alekperov R.T. Sildenafil in the treatment of Raynaud’s syndrome. Rheumatology Science and Practice. 2009;47(3):38-45. (In Russ.) https://doi.org/10.14412/1995-4484-2009-1311

Просмотров: 1166


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)